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From this national survey of the management of paediatric ocular inflammation, we report 
evidence of multi-disciplinary care, common use of systemic immunomodulation, and the 






Eye and child health specialists have recently come together to form the Paediatric Ocular 
Inflammation Group (POIG).1 POIG aims to inform management strategies, service 
commissioning and service delivery for children with sight threatening ocular inflammatory 
disorders. These disorders are united by their individual rarity, their complexity, and the use 
of potentially life-limiting systemic agents.  
Using an online survey distributed through the Royal College of Ophthalmologists 
(Supplementary file), POIG sought to identify ophthalmic consultants routinely managing 
childhood uveitis or inflammatory ocular surface, orbital or optic nerve disorders. Of the 44 
respondents, a third (17/44, 38%) managed all of these disorders (fig 1). Several specialists 
also managed adult disease: 14 of the 41 (46%) managing childhood uveitis; 10/27 (38%) 
orbital inflammation; 11/28 (39%) inflammatory ocular surface disorders (OSD); and 12 of 
the 22 (56%) ophthalmologists managing childhood optic neuritis. The majority had 
prescribed systemic immunomodulation / immunosuppression therapies: 30/41 in uveitis, 
17/27 in orbital inflammation (idiopathic orbital n=10, vasculitis related n=4, sarcoidosis 
n=2, and Behcet disease n=1), 6/28 OSD (blepharitic keratoconjunctivitis, KC n=4, atopic 
KC n=2, herpetic keratitis n=1) and 14/22 in optic neuritis. Of those using systemic therapies, 
the majority did so as part of a multi-disciplinary team: 20/30 in uveitis, 15/17 in orbital 
inflammation, 14/14 in optic nerve disorders, and 5/6 OSD. Biological immunomodulation 
therapies had been prescribed (through rheumatology colleagues) by 28 specialists managing 
childhood uveitis.  
Multi-disciplinary care was also reported in the surveillance of children at risk of uveitis due 
to Juvenile Idiopathic Arthritis. Examinations were carried out by allied health professionals 
in 12/38 (32%) settings (optometrists n=7, orthoptists n=5, nurses n=1).  
In summary the majority of responding clinicians managed more than one disorder, and often 
as part of a multi-disciplinary team.  Approximately half also manage adults. The survey was 
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‘opt-in’ in design, which may have resulted in under-ascertainment. However, an earlier 
national survey undertaken through the College identified a similar number (47) of UK 
surgeons managing congenital and infantile cataract,2 a disorder which has an incidence of 3-
4 per 10,000, thus ten-fold more common than childhood uveitis, which has a reported UK 
incidence of 5 per 100,000.3 Nevertheless, there may have been under-ascertainment of 
clinicians managing mild disease. 
Our findings suggest that half of all children with rare inflammatory eye disease are under 
specialists who do not manage adult disease. As the prognosis improves for children with rare 
eye disease, greater numbers will survive into adulthood with good vision.  Effective 
transition processes are needed to prevent patient disengagement from care.4 This is 
particularly important when care is shared between different services. We currently lack a 
consensus on best practice for transitional care for this group.   
Collaborative national networks for rare disease have been recognised as a research priority 
by NHS England, particularly those networks which work to improve rare disease outcomes.5  
POIG has identified key clinicians managing these disorders (fig 1), and aims to develop the 
evidence base necessary to improve outcomes for individuals with (or at risk of) rare, 
childhood onset ocular inflammatory disorders.  
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Titles and legends to figure.  
Figure 1. Childhood ocular inflammatory disorders managed by survey respondents 
 

